Acarbose

Verdict: Probable (in mice — strongly male-biased) / Suggestive (translation to humans) Last reviewed: 2026-04-25 Triangulated against anchor: Rapamycin (Probable) — same evidence shape, narrower human data

TL;DR

Acarbose is one of the largest-effect lifespan-extending compounds ever identified by the ITP — +22% median lifespan in males, +5% in females in genetically heterogeneous mice. The combination of rapamycin + acarbose extended median lifespan even further (+34% males, +28% females). It is FDA-approved for diabetes, generic, low-cost, well-tolerated. Human aging-endpoint trials don't exist. Verdict: Probable in mice; Suggestive in humans — one of the most underappreciated interventions in the longevity discourse given its evidence quality.

What it is

An α-glucosidase inhibitor that slows intestinal carbohydrate absorption, blunting post-prandial glucose spikes. Approved for type 2 diabetes management; modest A1C reduction. Typical dose: 50-100 mg with meals. Side effects (gas, bloating) are dose-limiting in some users; otherwise well-tolerated long-term.

Proposed mechanism

• Slowed carbohydrate absorption → blunted glucose / insulin excursions → reduced systemic mTOR / IGF-1 signaling
• Mimics partial caloric restriction at the gut level
• Microbiome shifts — likely a meaningful component, increasingly studied
• Effects on bile acid signaling and short-chain fatty acid production

Confidence: Established for the carbohydrate-absorption mechanism; Plausible for the lifespan-extension translation through CR-like signaling.

Evidence ladder

Animal models (T3 — strong)

• ITP positive across multiple cohorts (Harrison 2014, Strong 2016, Strong 2022 combination). Median lifespan extension:
  • Males: ~22% (single-drug)
  • Females: ~5% (single-drug)
• Rapamycin + acarbose combination (Strong 2022, ITP): median lifespan +34% males, +28% females. One of the largest combined effects observed in the ITP.
• Mechanism studies in mice (Smith, Harrison, Miller groups) — consistent with reduced glucose excursions / mTOR signaling.
• Sex-bias is real and replicated — males respond much more strongly. The metabolomic and microbiome signatures differ by sex; this is one of the cleanest sex-specific aging-intervention findings.

Human (T2 — and this is the gap)

• Diabetes RCTs establish glycemic control; mortality endpoint not powered.
• STOP-NIDDM (acarbose for diabetes prevention in IGT) — reduced cardiovascular events; secondary endpoint.
• No aging-endpoint trial exists. No NIH-funded TAME-equivalent for acarbose, despite the evidence base arguably being stronger than metformin's.
• Off-label longevity use is rising in the longevity-curious community; protocols are essentially extrapolated.

Confounds

• Sex bias — the male-biased effect raises mechanistic questions. Whether the mouse pattern translates depends on whether the underlying mechanism (glucose excursion blunting) interacts with sex-specific biology in humans similarly.
• Mouse strain — UM-HET3 may be particularly responsive; data in inbred strains is sparse.
• Microbiome contribution — the magnitude of effect through microbiome modulation vs direct glucose-excursion effect is debated.

Conflict of interest scan

• Generic drug, minimal commercial pressure. Independent academic / NIA-funded research.
• No discount applied.

Human translation

The honest decomposition:

1. In mice, acarbose is among the most effective ITP-tested longevity drugs, especially in males. T3 evidence on hard endpoint (lifespan).
2. In humans, the diabetes data establish safety and glycemic effect; no aging-endpoint trial exists.
3. The longevity rationale rests on extrapolation from mouse data + plausible CR-mimetic mechanism. This is methodology-permissible at the Probable-mice / Suggestive-humans level but does not justify Probable-humans claims.
4. Side effect profile (GI symptoms) limits adherence in some users; modern formulations improve tolerability.

For the longevity-curious: acarbose has arguably better mouse evidence than rapamycin, similar safety profile at low doses, and is broadly available. The case for it is at least as strong as for the more popular interventions, and substantially under-discussed.

Calibrated verdict

Probable (in mice) / Suggestive (in humans).

Compared to rapamycin (Probable), acarbose has comparable or better mouse evidence (larger effect size; strong combination data) but weaker human signal volume. The two interventions sit at roughly the same band when assessed honestly; rapamycin gets more public attention because of its higher-profile commercial / immunology trials.

Compared to metformin (Mixed), acarbose has substantially better mouse evidence (ITP positive vs ITP null for metformin alone). The popular discourse inverts this — metformin gets more attention despite weaker mouse evidence.

Confidence interval on verdict

• Mouse verdict: stable; ITP results are decisive.
• Human verdict: could move to Probable if any pre-registered aging-endpoint trial reports positive. Unlikely on near-term funding patterns.
• Most likely 2-year trajectory: stable; acarbose remains a "best-supported but un-trialed in humans for aging" outlier.

Open questions

• Q: Is anyone running an acarbose aging-endpoint RCT in non-diabetic adults? Funding status?
• Q: Why is the ITP effect so male-biased, and does that pattern have implications for human translation?
• Q: How much of the lifespan extension is mediated by microbiome shifts vs direct glucose-excursion blunting?
• Q: Are there optimal dosing protocols (with-meals only, lower doses, intermittent) that retain benefit while minimizing GI burden?

Sources

• Harrison et al. 2014, Aging Cell — Acarbose, 17α-estradiol, and NDGA extend mouse lifespan preferentially in males
• Strong et al. 2016, Aging Cell — ITP rapamycin + acarbose combination
• Strong et al. 2022 — ITP rapamycin + acarbose follow-up
• STOP-NIDDM — Acarbose for prevention of T2DM in impaired glucose tolerance
• Life extending drugs from ITP overview
• NIA ITP supported interventions

Produced under methodology locked 2026-04-24. Triangulated against rapamycin anchor.